Hence, we initially introduced the same mutations from the AEDDMF5 01 T cells into the α-chain of two additional TCR clones: TCR 1G4, with specificity to tumour-associated antigen NY-ESO-1 (peptide, SLLMWITQC (SLL))32 and a3a TCR, a previously engineered TCR with high affinity to the melanoma-associated MAGE-A3 antigen (peptide, EVDPIGHLY (EVD))28,29 (Supplementary Fig. 4a,b). The gene discussed is MAGEA3; the disease is melanoma.